EGFR and non-small cell lung carcinoma: Alterations occurring in the EGFR gene, especially those in exons 18 to 21, are determinants for response to tyrosine kinase inhibitors (TKIs), a class of targeted therapies that have significantly improved prognosis in NSCLC patients [9,10,23,24].